All News

Memory B cells are dysfunctional in #SLE. They are anergic B cell receptor signalling, but responsiveness to Toll-like receptor (TLR) and type I interferon signalling. BCR hyporesponsiveness of memory B cells may explain failure non-depleting B cell Rx in SLE… https://t.co/naBYtgLBGd https://t.co/5sJibS9esn
Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Dr. Quotes (11.8.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
COVID.virus_.corona.jpg (keep)

COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders

d Jack Cush, MD

A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.

Read Article
refridge.crisper.storage.jpg

EULAR Review of Lifestyle Improvements for Rheumatic Patients

d Jack Cush, MD

A EULAR taskforce has evaluated the effect of lifestyle behaviors in rheumatic and musculoskeletal diseases (RMDs) and concluded that there is moderate evidence for a small benefit for certain dietary components, but overall, high-level evidence regarding dietary exposures on outcomes in RMDs is lacking.

Read Article
Iberdomide Efficacy in Cutaneous Lupus berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk
Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush RheumNow ( View Tweet)
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/or6vuCZASs https://t.co/UxzSR6yJO5
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitor Protective Effects in Lupus Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D). https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Happy Diwali (11.1.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

d Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

SGLT2 Inhibitor Protective Effects in Lupus

d Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
Surprise! Low-level proteinuria is more associated w/ proliferative LN and adverse long-term outcomes. Study of 249 SLE GN pts (median 33 yrs; proteinuria =2.2/D; 71% proliferative (PGN) - 60% PGN w ≤1 g/d proteinuria (more renal recovery) - 79% w/ 1-3g/d - 71% w/ ≥3 g/d… https://t.co/t0aqWn3NDS https://t.co/zqJlJfHzqU
Dr. John Cush RheumNow ( View Tweet)
Blue Collar Arthritis (10.25.2024) Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow. https://t.co/INcke6eLLC https://t.co/TGyxzmCrjv

Links:

Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb

Links:

Dr. John Cush RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today! https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw

Links:

Dr. John Cush RheumNow ( View Tweet)
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×